Back to Awarded Treatment Trials
Awarded Trial: 01T-073
Grant ID
01T-073
Illness
Schizophrenia
Primary Drug/Intervention
Tetrabenazine
Primary Dosage
12.5mg-75mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Remington
Sample Size
60
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
CGI, BPRS, Calgary Depression Scale
Results
Thirty patients with schizophrenia who were partially responsive to clozapine were enrolled. There was no advantage of tetrabenazine over placebo.
Publication
N/A
Link
N/A
PI Name
Gary Remington
Degree
MD
Center
Clarke Site
Institution
Centre for Addiction and Mental Health (CAMH)
Address
250 College Street
City or Town
Toronto
State or Province
Ontario
Zip or Postal Code
M5T 1R8
Country
Canada
Email Address
gary_remington@camh.net